Actinium Pharmaceuticals, Inc. — Q1 2013 Form 10-Q
Reporting period: Three months ended March 31, 2013. The interim financial statements are unaudited. Following a December 2012 share exchange accounted for as a reverse takeover, the company is a clinical-stage biotechnology business; it changed its name and domicile to Actinium Pharmaceuticals, Inc. in April 2013.
Business context and development
The company develops antibody-based cancer treatments, including alpha-particle immunotherapy. It had no approved products, commercial operations, or revenue. Management identified Actimab-A and Iomab-B as its primary development programs; other candidates were in physician-sponsored early-stage trials.
Financial performance and liquidity
| Metric | Q1 2013 | Q1 2012 / March 31, 2013 balance |
|---|---|---|
| Revenue | $0 | $0 in Q1 2012 |
| Research and development expense | $1.086 million | $444,886 in Q1 2012 |
| General and administrative expense | $933,135 | $560,276 in Q1 2012 |
| Total operating expenses | $2.023 million | $1.005 million in Q1 2012 |
| Net loss | $689,027 | $908,909 in Q1 2012 |
| Net loss per share, basic and diluted | $0.03 | $0.07 in Q1 2012 |
| Cash and cash equivalents | $3.240 million | $5.619 million at December 31, 2012 |
| Net cash used in operating activities | $2.312 million | $947,927 in Q1 2012 |
| Current assets / current liabilities | $3.357 million / $2.806 million | Working capital: $550,808 |
| Notes payable / derivative liabilities | $74,667 / $2.240 million | Both classified as current liabilities |
Cash fell by $2.379 million during the quarter. There was no financing inflow: the company repaid $65,333 under an insurance-premium financing arrangement. The filing reports no meaningful operating margin because there was no revenue. No dividends were expected for the foreseeable future.
Changes versus the prior comparable period
- R&D expense rose by $640,821, principally due to the Actimab-A multicenter trial, BC8 manufacturing, and development and regulatory work on Iomab-B.
- G&A expense increased by $372,859, reflecting professional fees, staffing, payroll, and stock-based compensation.
- Operating cash use increased by approximately $1.364 million, reflecting higher trial-related spending and professional and payroll costs.
- Net loss narrowed by $219,882 despite higher operating costs. A $1.335 million non-cash gain from the decrease in derivative-liability fair value contributed to the improvement; the comparable gain in Q1 2012 was $409,301. The filing cautions that derivative valuations use Level 3 inputs and management assumptions.
Outlook, risks, and unusual items
- Going concern: Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing recurring losses, $56.432 million accumulated deficit, operating cash use, and no stable recurring revenue source. Continued operations depend on raising capital; no funding commitments or assurance of availability were reported.
- Funding needs: The company estimated cash needs of up to $20 million in 2013 for R&D and working capital. If funding is insufficient, it may delay development programs and focus on the Actimab-A trial.
- Program costs and dependencies: Management estimated direct completion costs of approximately $7 million for the ongoing Actimab-A Phase I/II trial and $15–20 million for the planned Iomab-B pivotal trial. Success depends on clinical results, regulatory approval, collaborations, isotope and antibody supply, manufacturing, and intellectual-property protection.
- Contingencies and commitments: License agreements include future milestone and royalty payments, including Abbott milestones totaling $7.75 million and royalties of 12% of licensed-product net sales, and FHCRC royalties of 2% plus a $1 million approval milestone. The FHCRC trial development cost was estimated at $13.2–23.5 million depending on design. These are contingent or future amounts, not necessarily current liabilities.
- Other unusual items: A February 2013 settlement with the former CEO provides for $250,000 in two installments plus a $60,000 performance bonus. The company wrote off its remaining net property and equipment, recording a $4,122 loss.
- Controls and corporate updates: Management concluded disclosure controls and procedures were not effective as of March 31, 2013. The company changed its name and state of incorporation in April and began trading under ticker ATNM effective April 18. After quarter-end, 154,403 warrants were exercised through May 15.
Important facts for investors to verify
- Whether the company raised sufficient capital after the reporting date to fund its stated 2013 needs and address the going-concern uncertainty.
- Current cash, burn rate, outstanding debt, and fully diluted share count, including potential dilution from warrants and options.
- Clinical-trial progress, costs, regulatory plans, and any changes to the stated Actimab-A and Iomab-B timelines.
- The assumptions and sensitivity underlying the Level 3 derivative-liability valuation and related non-cash gains.
- Remediation of ineffective disclosure controls and the status of material license, trial, and settlement obligations.